Leading the Way in Life Science Technologies

GEN Exclusives

More »

Jun. 1, Vol. 25, No. 11

    • Columns

      • Anti-Cancer Therapy Success
      • John Wong, Ph.D.
      • Genentech (San Francisco) had a banner year from 1997 to 1998, when it received FDA approval to market its two monoclonal antibodies for treating cancers. In November 1997, Genentech received FDA approval to commercialize Rituxan (rituximab), to tre ... more »
      • Examining NIH Policy to Enhance Public Access
      • The increased public access policy to be effected by the National Institutes of Health (NIH) was originally conceived to change the way patent practioners interact with inventors of biologically or chemically based inventions. After receiving public ... more »
    • Feature Articles

      • Functional Genomics Reveals Mysteries of Genes
      • Many companies are shifting their focus from genome mapping and sequencing to determining gene function. Functional genomics uses a range of technologies for genome-wide analyses supported by data interpretation. These activities depend on experimen ... more »
      • Greater Philly Region Grows as a Bio Cluster
      • BIO's annual conference, which will be held in Philadelphia later this month, highlights the fact that Southeastern Pennsylvania represents a significant focus of biotech and pharmaceutical activity. Indeed, recent developments reinforce the are ... more »
      • Mass Spectrometry in the Life Science Market
      • Though originally employed in academic exercises during the early part of the last century to characterize the masses and determine the stabilities of nuclear isotopes, the practicality of mass spectrometry (MS) was quickly realized. During the 194 ... more »
      • Oligo Manufacturing Puts Emphasis on RNA
      • As more experimental DNA drugs move through the clinic and into large-scale trials, the demand for efficient and cost-effective manufacturing strategies is intensifying. Higher yields, greater purity, and lower production costs are the key drivers o ... more »
      • Optimizing the Drug Target Search
      • Susan Aldridge, Ph.D.
      • The last few years have seen some dramatic changes in the field of drug discovery, but there is an urgent need to make R&D more cost effective, according to Alex Matter, Ph.D., director of the Novartis Institute for Tropical Diseases (Singapore) ... more »
      • Trends in Incubator and Shaker Technologies
      • Preventing contamination using thermal decontamination routines and the upcoming use of oxygen control could be seen as trends in incubation, according to Rainer Zagst, product marketing manager of Kendro Laboratory Products (www. kendro.spx.com). T ... more »
      • Ways to Overcome the Small Molecule Curse
      • Oral bioavailability, access to intracellular targets, and cost and ease of production are a few advantages that small molecule drugs generally have over large molecule drugs such as biologics, natural products, and peptides. These properties make s ... more »
    • Tutorials

      • Applying PAT to Oligonucleotide Synthesis
      • Oligonucleotides are short strands of DNA or RNA that play a major role in drug discovery and molecular diagnostic chip technology. They are used from initial research and screening through to target validation and drug production. Developers of ol ... more »
      • Integrated Workflow for Development Testing
      • In response to the realization that many products have failed due to formulation issues, pharmaceutical companies are putting much more emphasis on achieving optimal product formulations earlier in the development process. Using traditional manual e ... more »
      • Microarray Data Management and Analysis
      • In microarray gene expression experiments, several diverse conditions in each experiment (e.g., time, doses, replicates) increase the data points from tens of thousands of measurements for a single array to millions for the experiment as a whole. F ... more »

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »